Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).
Haimaplex;Preconativ;Profilnine;Proplex;Prothromplex.
World Health Organization (WHO)
Factor IX, a naturally occurring plasma protein fraction, is a vital
component of the normal blood clotting mechanism which is deficient in
haemophiliacs who require replacement therapy for both the treatment and
prevention of bleeding. Factor IX is extracted from the pooled plasma of a large
number of donors and is presented as a concentrate. It has been recognized since
1984 that some viruses, and particularly the HIV (AIDS virus) could be transmitted
to haemophiliacs from such preparations. As a result many regulatory authorities
have issued new directives for the manufacture of blood products that avert this danger, by requiring the introduction of specific antiviral treatment measures
during the manufacturing process. Manufacturers have withdrawn pre-existing
preparations.
Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.
